<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413618</url>
  </required_header>
  <id_info>
    <org_study_id>RIDILOTT-DVT</org_study_id>
    <nct_id>NCT03413618</nct_id>
  </id_info>
  <brief_title>Rivaroxaban With Diosmine in Long-term Treatment of DVT</brief_title>
  <acronym>RIDILOTT-DVT</acronym>
  <official_title>The Efficacy of Rivaroxaban With Diosmine in the Long-term Treatment of Acute Proximal Deep Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pirogov Russian National Research Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pirogov Russian National Research Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized clinical study aimed to assess the efficacy and safety of standard
      anticoagulation with rivaroxaban in combination with diosmin compared to the isolated use of
      standard rivaroxaban for prolonged therapy of acute femoro-popliteal deep vein thrombosis
      reflected the speed of deep vein recanalization and incidence of post-thrombotic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep vein thrombosis is an acute inflammatory disease that affects vein wall and leads to the
      structural changes in the wall and valves reflected with chronic venous insufficiency that
      called postthrombotic syndrome (PTS).

      Diosmin as a flavonoid agent has properties to reduce leukocyte-endothelial interaction and
      inflammatory response, that could reduce the damage to venous wall and valves.

      The hypothesis of the study is based on assumption that diosmin combined with standard
      anticoagulation can improve outcomes of femoro-popliteal DVT due to increase speed of veins
      recanalization, decrease of vein wall inflammation and finally decrease the incidence of PTS
      at 6 month and 1 year after index DVT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized open-labeled clinical trial with a masked outcomes assessor</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor does not involve in randomisation and treatment process, has no information about the patient's belonging to one of the study groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>postthrombotic syndrome</measure>
    <time_frame>12 month</time_frame>
    <description>detection of postthrombotic syndrome according to the Villalta score (5+ scores)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrent symptomatic or asymptomatic deep vein thrombosis</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 month</time_frame>
    <description>detection of any episode of recurrent DVT with or without clinical signs verified by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic pulmonary embolism</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 month</time_frame>
    <description>detection of symptomatic pulmonary embolism verified with CT pulmonary angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of chronic venous disease</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>the severity of chronic venous disease assessed with VCSS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>the quality of life assessed with CIVIQ-20 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>degree of the residual venous obstruction</measure>
    <time_frame>2, 4, 6, 8, 10, 12 month</time_frame>
    <description>the degree of the residual venous obstruction assessed by the compressibility of the main venous segments (femoral vein, superficial femoral vein, popliteal femoral vein) by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extension of residual venous obstruction</measure>
    <time_frame>2, 4, 6, 8, 10, 12 month</time_frame>
    <description>the extension of residual venous obstruction (thrombotic masses occupying 20% and more of the vein cross-sectional diameter) assessed by the modified Marder score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 month</time_frame>
    <description>any adverse events detected or suspected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 month</time_frame>
    <description>according to ISTH definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically relevant non-major bleeding</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 month</time_frame>
    <description>any non-major bleeding requiring anticoagulant withdrawal, and/or performing haemostatic measures, and/or hospitalization, and/or an unscheduled medical appointment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minor bleeding</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 month</time_frame>
    <description>any non-major or non-clinically relevant bleeding does not require the suspension of therapy and changes in the patient's lifestyle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Postthrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month</description>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>600 mg q.d. for 12 month</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>flebodia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compression stockings</intervention_name>
    <description>above knee stocking for 12 month</description>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  The first episode of femoro-popliteal deep vein thrombosis

          -  Verification of DVT by duplex ultrasound

          -  Informed consent signed

        Exclusion Criteria:

          -  Suspicion of PE

          -  Verified PE

          -  Bilateral DVT

          -  Contraindications for rivaroxaban (in accordance with the official instructions)

          -  Contraindications for diosmin (in accordance with the official instructions)

          -  Active cancer

          -  Verified severe thrombophilia (APL, deficiency of proteins C, S, AT-3)

          -  Use of other anticoagulants for more than 7 days from the DVT verification

          -  Impossibility of using compression stocking after 3 days from DVT verification

          -  Performed surgical intervention on the superficial or deep veins of the lower
             extremities (thrombolysis, thrombectomy, vein ligation, implantation of the inferior
             cava filter)

          -  Continuous use of other drugs that affect the hemostasis system (except for ASA in a
             dose of not more than 100 mg).

          -  Low compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya Schastlivtsev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pirogov Russian National Research Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilya Schastlivtsev, PhD</last_name>
    <phone>+7-905-541-89-48</phone>
    <email>schastlivtsev.ilya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kirill Lobastov, PhD</last_name>
    <phone>+7-985-211-63-31</phone>
    <email>lobastov_kv@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Hospital no.1 of the President's Administration of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121352</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirill Lobastov, PhD</last_name>
      <phone>+7-985-211-63-31</phone>
      <email>lobastov_kv@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Victor Barinov</last_name>
      <phone>+7-916-609-43-19</phone>
      <email>vicbarin@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Barinov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilya Schastlivtsev</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kirill Lobastov</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>postthrombotic syndrome</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>treatment</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

